



Universitätsklinik für Urologie und Andrologie

Landeskrankenhaus; Müllner Hauptstr. 48; A-5020 Salzburg

Vorstand: Prim. Univ. Prof. Dr. Lukas Lusuardi



Studienteam:

Prim. Univ. Prof. Dr. Lukas Lusuardi; Principal Investigator

Dr. Thomas Kunit; Leiter organspezifische Studiengruppe Prostata

Priv.-Doz. Dr. Daniela Colleselli M.Sc.; Leiterin organspezifische Studiengruppe Blase

Priv.-Doz. Dr. Michael Mitterberger; Leiter organspezifische Studiengruppe Niere

Dr. Martin Drerup; Leiter Studien der Inkontinenz und urologische Infektionen

Bethseba Plank BMA; 1. Study Nurse

Feliza Tungaia-Schwank BMA; 2. Study Nurse

DDr. Ljiljana Milinovic; Studienkoordinatorin

Kontakt: lmilinovic@salk.at

Patientenpopulation: ca. 15000 ambulante Patienten/Jahr

Klinische Studien offen:

SP005 Viable SOTIO A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapy.

EMBARK MDV3100-13 Medivation Astellas A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy

SAUL MO29983 Roche An open label, single arm, multicenter, safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

IMMOTION WO39210 Roche A phase 3, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy

ADONIS Pfizer InLyTA in advanced / metastatic renal cell carcinoma - a non-interventional study of real world treatment outcomes in patients receiving 2nd line InLyTA after 1st line sunitinib

Ignite3 TP-434-021 Thetraphase A phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with ertapenem in complicated urinary tract infections

Klinische Studien in Follow up:

Prevail MDV3100-03 *Medivation Astellas*;
Reassure Xofigo *Bayer*; VEG 113387
Pazopanib und VEG 115232 Principal
GlaxoSmithKline ...

Klinische Studien abgeschlossen:

Ipilimumab CA184-043 *Bristol-Myers Squibb*
2008-003314-97; SWITCH TU München
iOMEDICO; PROTECT *GlaxoSmithKline*
NCT01235962; SANO2011 Hypericin
Sanochemia; JASIMA *Pierre Fabre Pharma GmbH*;
Abiraterone COU-AA-301 *Cougar*;
AMG 386 *Amgen* 20060159; Denosumab
Amgen/PPD 20050103; TAX J3501 *Sanofi*
Aventis XRP6976J/3501; AUPSG 01-07;
ICELAND Astellas: EGD-EC-003
ELIGARD; CONCERT *Bayer* NCT00678288;
Neptune 905-CL-055 + 905-CL-057 2008-
001211-37; Ipilimumab CA184-043 *Bristol-Myers Squibb*;
EORTC 30994; EORTC 30986
EORTC 30985; EORTC 30983; EORTC
30962; EORTC 30911...

Akademische Kooperationspartner:

ÖGU Österreichische Gesellschaft für Urologie
EAU European Association of Urology
DGU Deutsche Gesellschaft für Urologie
ESPU European Association for Pediatric Urology
EBU European Board of Urology
SIU Società italiana di urologia
EORTC European Organisation for Research and Treatment of Cancer
CROES Clinical Research Office of the Endourological Society

PMU Privatmedizinische Universität Salzburg
LMU Ludwig-Maximilian Universität München
UULM Universität Ulm
I-Med Medizinische Universität Innsbruck
Ordens Klinikum Linz

Kooperationspartner Industrie :



Pierre Fabre

